Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553455 | 0.85 | TLR2 (0.55) | PTPN1KMT2ATLR2CASP3 | |
| SCHEMBL21187795 | 0.84 | KMT2A (0.56) | PTPN1KMT2ACASP3PIN1 | |
| SCHEMBL31326505 | 0.84 | KMT2A (0.56) | PTPN1KMT2ACASP3PIN1 | |
| SCHEMBL12966414 | 0.84 | KMT2A (0.56) | PTPN1KMT2ACASP3PIN1 | |
| SCHEMBL29398874 | 0.84 | KMT2A (0.56) | PTPN1KMT2ACASP3PIN1 | |
| SCHEMBL38660483 | 0.84 | KMT2A (0.56) | PTPN1KMT2ACASP3PIN1 | |
| SCHEMBL16257642 | 0.83 | KMT2A (0.52) | KMT2ATLR2CASP3 | |
| SCHEMBL14326310 | 0.83 | CASP3 (0.50) | KMT2ACASP3PIN1 | |
| SCHEMBL16000769 | 0.83 | CASP3 (0.50) | KMT2ACASP3PIN1 | |
| SCHEMBL24579257 | 0.83 | CASP3 (0.50) | KMT2ACASP3PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205463-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205463-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | FCGR2A, FCGRT, FCGR1A | PTPN1 1318/4885KMT2A 1026/4885TLR2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.